Ahmet Muzaffer Demir

Ahmet Muzaffer Demir

Auto-generated profile, based on publicly available information

Ahmet Muzaffer Demir

Trakya Universitesi, Tip Fakultesi

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2018 in Turkish Journal of Gastroenterology
Verified
Journal Article
Closed access
BABilgehan Aygen
Bilgehan Aygen
ADAhmet Muzaffer Demir
Ahmet Muzaffer Demir
MGMahmut Gumus
Mahmut Gumus
OKOguz Karabay
Oguz Karabay
SKSabahattin Kaymakoğlu
Sabahattin Kaymakoğlu
FTFehmi Tabak
Fehmi Tabak
This consensus report includes expert opinions and recommendations regarding the screening, and if necessary, the follow-up, prophylaxis, and treatment of hepatitis B before the treatment in patients who will undergo immunosuppressive therapy due to an emergency risk of hepatitis B reactivation. To increase awareness regarding the risk of hepatitis B reactivation in immunosuppressive patients, academicians from several university health research and training centers across Turkey came together and discussed the importance of the subject, current status, and issues in accordance with the current literature data and presented solutions. Cite this article as: Aygen B, Demir AM, Gümüş M, et al. Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report. Turk J Gastroenterol 2018; 29: 259-69.

7 October 2008 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Closed access
BGBaburhan Guldiken
Baburhan Guldiken
MDMuzaffer Demir
Muzaffer Demir
SGSibel Guldiken
Sibel Guldiken
NTNilda Turgut
Nilda Turgut
BTBurhan Turgut
Burhan Turgut
ATArmagan Tugrul
Armagan Tugrul
Free radical formation is the pivotal mechanism of neuronal injury of ischemic and reperfused brain tissue. In healthy individuals, antioxidant activity counterbalances free radical production, but in the case of ischemia, the balance between reactive oxygen species and antioxidant activity is shifted toward free radicals, causing oxidative stress. The aim of this study is to assess total antioxidant capacity (TAC) and oxidative stress in diabetic and nondiabetic acute stroke patients with 2 different stroke subtypes: large and small vessel disease stroke. Sixty-five acute ischemic stroke patients (29 diabetic and 36 nondiabetic) and 20 age-matched healthy control subjects were recruited in the study. Plasma TAC and nitric oxide (NO) metabolite levels (nitrite and nitrate) were measured by enzyme-linked immunosorbent assay. The subtypes of stroke were defined according to Trial of Org 10172 in Acute Stroke Treatment criteria. The main findings of this study are that the TAC and NO levels were significantly higher in diabetic acute stroke patients than in nondiabetic patients and control cases (P < .001 and P < .001, respectively). The TAC and NO levels were higher also in nondiabetic stroke patients than in controls, but the difference did not reach any significance. No difference was found between NO and TAC levels in large and small vessel stroke subtypes of diabetic and nondiabetic patients. The authors conclude that oxidative stress and counterbalancing antioxidant capacity are more pronounced in diabetic acute stroke patients than in nondiabetic acute stroke patients.

5 September 2020 in European Journal of Cancer Care
Verified
Journal Article
Closed access
PDF file
EUElif G. Umit
Elif G. Umit
UKUlku Korkmaz
Ulku Korkmaz
MBMehmet Baysal
Mehmet Baysal
SGSedanur Karaman Gulsaran
Sedanur Karaman Gulsaran
VBVolkan Bas
Volkan Bas
ADAhmet Muzaffer Demir
Ahmet Muzaffer Demir

1 March 2022 in International Journal of Hematologic Oncology
Verified
Journal Article
Open access
GSGuray Saydam
Guray Saydam
RARidvan Ali
Ridvan Ali
ADAhmet Muzaffer Demir
Ahmet Muzaffer Demir
AEAhmet Emre Eskazan
Ahmet Emre Eskazan
BGBirol Guvenc
Birol Guvenc
OIOsman Ilhan
Osman Ilhan
Tyrosine kinase inhibitors (TKIs) approved for chronic myeloid leukemia known to have similar efficacies but different safety profiles. Therefore, the choice of patient-specific treatments is driven by factors such as tolerability and adverse event profile of TKIs. This review article examines the most up-to-date data and provides practical recommendations for clinical approaches. Nilotinib and ponatinib should be avoided in patients with cardiovascular risk factors, dasatinib in patients with lung damage and bosutinib and nilotinib in patients with liver disease. Considering that certain comorbidities predispose some patients to developing severe adverse events when receiving TKIs, the first- and second-line treatment of chronic myeloid leukemia should be tailored to each patient’s individual condition.

24 February 2022 in Turkish Journal of Hematology
Verified
Journal Article
Open access
SBSinem Civriz Civriz Bozdag
Sinem Civriz Civriz Bozdag
GSGuldane Cengiz Seval
Guldane Cengiz Seval
IYIpek Yonal-Hindilerden
Ipek Yonal-Hindilerden
FHFehmi Hindilerden
Fehmi Hindilerden
NANeslihan Andıç
Neslihan Andıç
GÖGüner Hayri Özsan
Güner Hayri Özsan
Objective: Patients with solid malignancies are more vulnerable to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection than the healthy population. The outcome of SARS-CoV-2 infection in highly immunosuppressed populations, such as in patients with hematological malignancies, is a point of interest. We aimed to analyze the symptoms, complications, intensive care unit admissions, and mortality rates of patients with hematological malignancies infected with SARS-CoV-2 in Turkey. Materials and Methods: In this multicenter study, we included 340 adult and pediatric patients diagnosed with SARS-CoV-2 from March to November 2020. Diagnosis and status of primary disease, treatment schedules for hematological malignancies, time from last treatment, life expectancy related to the hematological disease, and comorbidities were recorded, together with data regarding symptoms, treatment, and outcome of SARS-CoV-2 infection. Results: Forty four patients were asymptomatic at diagnosis of SARSCoV-2 infection. Among symptomatic patients, fever, cough, and dyspnea were observed in 62.6%, 48.8%, and 41.8%, respectively. Sixtynine (20%) patients had mild SARS-CoV-2 disease, whereas moderate, severe, and critical disease was reported in 101 (29%), 71 (20%), and 55 (16%) patients, respectively. Of the entire cohort, 251 (73.8%) patients were hospitalized for SARS-CoV-2. Mortality related to SARS-CoV-2 infection was 26.5% in the entire cohort; this comprised 4.4% of those patients with mild disease, 12.4% of those with moderate disease, and 83% of those with severe or critical disease. Active hematological disease, lower life expectancy related to primary hematological disease, neutropenia at diagnosis of SARS-CoV-2, ICU admission, and first-line therapy used for coronavirus disease-2019 treatment were found to be related to higher mortality rates. Treatments with hydroxychloroquine alone or in combination with azithromycin were associated with a higher rate of mortality in comparison to favipiravir use. Conclusion: Patients with hematological malignancy infected with SARS-CoV-2 have an increased risk of severe disease and mortality.

25 February 2021 in Turkish Journal of Hematology
Verified
Journal Article
Open access
MBMehmet Baysal
Mehmet Baysal
EÜElif Ümit
Elif Ümit
HKHakki Onur Kirkizlar
Hakki Onur Kirkizlar
ADAhmet Muzaffer Demir
Ahmet Muzaffer Demir
Several clinical scoring systems have been developed for the differential diagnosis of thrombotic microangiopathies (TMA), all to predict and identify patients with ADAMTS13 deficiency and to start the treatment as soon as possible. The first scoring system in this regard is Bentley score; and French score and Plasmic scores were developed afterwards. We aimed to evaluate the laboratory parameters and clinical features of patients who underwent plasma exchange with a pre-diagnosis of TTP at our clinic between 2007 and 2019 and whose ADAMTS13 enzyme level was measured and to compare with the scoring systems. Data of 35 patients were evaluated. Twelve patients were evaluated as high risk according to all 3 scoring systems. Statistically significant relation was observed between all 3 scoring systems and ADAMTS13 levels. In addition moderate correlation was found between all 3 scoring systems and ADAMTS13 levels. We observed a similar potential strength of all three scoring systems to predict TTP within other TMAs and are applicable in daily practice.